Analysis of clinical significance of procalcitonin in small-cell lung cancer

Analysis of clinical significance of procalcitonin in small-cell lung cancer - Procalcitonin in SCLC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035975

Enrollment

Registered

2019-02-22

Start date

2012-02-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who receive chemotherapy and/or radiotherapy for small cell lung cancer in Niigata University Medical and Dental Hospital.

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

Measure	Time frame
Association between the concentration of procalcitonin and overall survival in small cell lung cancer patients.	—

Secondary

Measure	Time frame
1. Association between the concentration of procalcitonin and response rate, progression-free survival in small cell lung cancer patients. 2. Association between the concentration of procalcitonin and bacterial infection.	—

Countries

Japan

Contacts

Public ContactSatoshi Watanabe

Niigata University Medical and Dental Hospital Department of Respiratory Medicine and Infectious Diseases

satoshi7@med.niigata-u.ac.jp0253689325

Outcome results